Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: UHS stock price vs SUPN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SUPN's multiple
Needs SUPN P/E.
Implied fair value · at UHS's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
UNIVERSAL HEALTH SERVICES INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
SUPERNUS PHARMACEUTICALS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HCA Healthcare, Inc.
UHS vs HCA
TENET HEALTHCARE CORP
UHS vs THC
COMMUNITY HEALTH SYSTEMS INC
UHS vs CYH
ACADIA PHARMACEUTICALS INC
UHS vs ACAD
Encompass Health Corp
UHS vs EHC
Jazz Pharmaceuticals plc
UHS vs JAZZ
INCYTE CORP
UHS vs INCY
ANI PHARMACEUTICALS INC
UHS vs ANIP
Vanda Pharmaceuticals Inc.
UHS vs VNDA
Harmony Biosciences Holdings, Inc.
UHS vs HRMY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe UHS should be valued more on its profitable operations and capital efficiency than on SUPN-based P/S anchor, then avoid relying on the $984.00 implied price and instead focus on the historical and DCF ranges, because UHS already trades below the DCF range but above the lower end of its own historical band.
The comparison shows a dramatic disconnect between UHS's current price of $168.44 and SUPN-implied price of $984.00, which implies 484.2% upside under the stated P/S framework. However, that implied value is driven by a SUPN with much lower revenue but a structurally different profile, so the gap looks more like a model artifact than a clean comparable-valuation signal.
Supporting Metrics
